Trending Now
Nio Inc (NYSE:NIO) gets an upgrade from Bank of America
The year 2022 has been nothing but dismal for share holders of Nio Inc (NIO). Share prices have lost over 50% value...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Halozyme ($HALO): Analyzing the Latest Wall Street Insights and Forecasts
Halozyme Therapeutics (HALO) has been attracting considerable attention from Wall Street analysts, and for good reason. As a biopharmaceutical company specializing in...
MAKE IT MODERN
LATEST REVIEWS
The Big Picture for Virus Testing Stocks (FLGT, ALST, CODX)
The good news is that the end of the pandemic is in sight. The bad news is that it may never really...
MAKE IT MODERN
PERFORMANCE TRAINING
Annovis Bio (NASDAQ: ANVS) Tanks On Disappointing Posiphen Study Results
Annovis Bio (NASDAQ: ANVS) stock tanked on Thursday after its touted Alzheimer's disease drug flopped and failed to show a significant difference in a...
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Announce Promising Results Of Cosibelimab in Treating mCSCC
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) has announced interim results of its on-going open-label, multicohort, global Phase 1 clinical study of cosibelimab, its PD-L1 antibody in...
AI and Blockchain Converge with BLGI Inc (OTCMKTS:BLGI)
Two of the most important trends defining the intermediate-term future are starting to coalesce, as both blockchain and artificial intelligence are increasingly implicated in...
Cardiff Oncology Inc. (NASDAQ: CRDF) Releases New Data On Onvansertib in KRAS-Mutated mCRC Treatment
Cardiff Oncology Inc. (NASDAQ: CRDF) has announced the latest data from its clinical program investigating the combination of onvansertib with the standard of care...
Vistagen Therapeutics Inc (NASDAQ: VTGN) Reports Revenues Of $1.1 Million From Sublicenses In 2021:...
Vistagen Therapeutics Inc (NASDAQ: VTGN) posted revenues of $1.1 million in 2021 from its sublicense revenues related to the non-dilutive upfront payment of $5.0...
MAKE IT MODERN
